QQQ
+ 2.79
384.33
+ 0.72%
BTC/USD
-8.43
56471.91
-0.01%
DIA
+ 6.13
334.33
+ 1.8%
SPY
+ 6.44
444.06
+ 1.43%
TLT
+ 0.19
152.15
+ 0.12%
GLD
-0.96
167.12
-0.58%

Up In Smoke? DoJ Will 'Take Action' Against States That Have Legalized Marijuana

by
February 24, 2017 9:58 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Despite major Election Day victories in eight out of nine states in November, the U.S. marijuana movement may now be derailed.

It seems the worst-case scenario could be unfolding for marijuana investors and supporters. White House spokesperson Sean Spicer told reporters Thursday that President Trump and Attorney General Jeff Sessions intend to spearhead “greater enforcement” of the federal marijuana ban.

“There are two distinct issues here: medical marijuana and recreational marijuana,” Spicer said. “There’s still a federal law that we need to abide by when it comes to recreational marijuana and other drugs of that nature.”

While Spicer seemed to be drawing a distinction between recreational and medical marijuana use, Height Securities points out that the law draws no such distinction.

“Under current federal law, however, there is no distinction between intended use in how the drug is classified/should be viewed by federal law enforcement,” the firm wrote in a research note.

In other words, by the letter of the law, a federal marijuana crackdown should impact both the medical and recreational marijuana markets equally.

Related Link: Earth Science Tech: Another Marijuana Stock That Looks 'Insanely Overvalued'

“While shutting down ‘recreational’ cannabis would be a tremendous blow to the industry, Spicer made it very clear that ‘medical’ cannabis is sacrosanct,” Alan Brochstein, founding partner at New Cannabis Ventures and founder of 420 Investor, told Benzinga. “I would argue that a medical-only industry will still be a large and growing industry.”

GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH) spokesperson Stephen Shultz tells Benzinga its cannabinoid drug candidates should not be impacted by any potential crackdown in federal enforcement.

“Once a Schedule 1 drug that is based on cannabinoids is approved by the FDA, then there’s an automatic process for rescheduling of that approved medicine, not for marijuana or cannabis in general, but just for the compound that was approved by the FDA," Shultz explained.

Schultz said if the company's Epidiolex drug is approved by the FDA, investors can expect cannabidiol to be rescheduled and federally legalized shortly thereafter.

In that respect, shareholders of GW Pharmaceuticals, Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) and other marijuana-based biotech stocks shouldn't be particularly concerned about the federal crackdown.

It remains to be seen what exactly Trump will do to enforce federal marijuana laws, but Americans living in states with legalized medical or recreational marijuana may soon no longer have easy access to the drug.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

PreMarket Prep Stock Of The Day: GW Pharmaceuticals

PreMarket Prep Stock Of The Day: GW Pharmaceuticals

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. read more
GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020

GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020

BofA Sees Blockbuster Sales Potential For GW Pharma's CBD Drug Epidiolex

BofA Sees Blockbuster Sales Potential For GW Pharma's CBD Drug Epidiolex

GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year

GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year